Hanmi Pharm. Co., Ltd. (128940.KS)
KRW 269500.0
(-1.46%)
KRW 269500.0
(-1.46%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 835.85 Billion KRW | 16.32% |
| 2022 | 718.55 Billion KRW | 13.56% |
| 2021 | 632.75 Billion KRW | 8.92% |
| 2020 | 580.91 Billion KRW | -8.15% |
| 2019 | 632.48 Billion KRW | 16.93% |
| 2018 | 540.91 Billion KRW | 4.34% |
| 2017 | 518.4 Billion KRW | 12.49% |
| 2016 | 460.85 Billion KRW | -49.87% |
| 2015 | 919.28 Billion KRW | 117.58% |
| 2014 | 422.5 Billion KRW | 1.45% |
| 2013 | 416.45 Billion KRW | 5.52% |
| 2012 | 394.67 Billion KRW | 18.05% |
| 2011 | 334.33 Billion KRW | 71.43% |
| 2010 | 195.03 Billion KRW | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 206.67 Billion KRW | -8.75% |
| 2024 Q3 | 362.07 Billion KRW | -3.9% |
| 2024 Q1 | 226.48 Billion KRW | -7.86% |
| 2023 Q2 | 180.18 Billion KRW | -12.98% |
| 2023 Q3 | 198.84 Billion KRW | 10.36% |
| 2023 Q4 | 245.8 Billion KRW | 23.61% |
| 2023 FY | 835.85 Billion KRW | 16.32% |
| 2023 Q1 | 207.06 Billion KRW | 8.24% |
| 2022 FY | 718.55 Billion KRW | 13.56% |
| 2022 Q4 | 191.3 Billion KRW | 1.46% |
| 2022 Q3 | 188.54 Billion KRW | 13.61% |
| 2022 Q1 | 172.74 Billion KRW | -6.49% |
| 2022 Q2 | 165.96 Billion KRW | -3.92% |
| 2021 Q2 | 141.4 Billion KRW | -3.32% |
| 2021 Q1 | 146.25 Billion KRW | -8.91% |
| 2021 Q4 | 184.72 Billion KRW | 15.2% |
| 2021 Q3 | 160.35 Billion KRW | 13.4% |
| 2021 FY | 632.75 Billion KRW | 8.92% |
| 2020 Q2 | 129.75 Billion KRW | -20.98% |
| 2020 Q3 | 126.4 Billion KRW | -2.58% |
| 2020 Q4 | 160.56 Billion KRW | 27.02% |
| 2020 FY | 580.91 Billion KRW | -8.15% |
| 2020 Q1 | 164.19 Billion KRW | -4.17% |
| 2019 Q2 | 144.63 Billion KRW | -10.95% |
| 2019 Q4 | 171.33 Billion KRW | 11.19% |
| 2019 FY | 632.48 Billion KRW | 16.93% |
| 2019 Q1 | 162.41 Billion KRW | 17.8% |
| 2019 Q3 | 154.09 Billion KRW | 6.54% |
| 2018 Q2 | 133.39 Billion KRW | -5.98% |
| 2018 FY | 540.91 Billion KRW | 4.34% |
| 2018 Q4 | 137.87 Billion KRW | 7.91% |
| 2018 Q3 | 127.76 Billion KRW | -4.22% |
| 2018 Q1 | 141.87 Billion KRW | 15.07% |
| 2017 Q4 | 123.29 Billion KRW | -8.79% |
| 2017 FY | 518.4 Billion KRW | 12.49% |
| 2017 Q2 | 125.53 Billion KRW | -6.6% |
| 2017 Q1 | 134.39 Billion KRW | 98.41% |
| 2017 Q3 | 135.17 Billion KRW | 7.68% |
| 2016 FY | 460.85 Billion KRW | -49.87% |
| 2016 Q1 | 143.8 Billion KRW | -70.3% |
| 2016 Q2 | 126.26 Billion KRW | -12.2% |
| 2016 Q4 | 67.73 Billion KRW | -44.95% |
| 2016 Q3 | 123.04 Billion KRW | -2.55% |
| 2015 Q2 | 146.78 Billion KRW | 25.93% |
| 2015 FY | 919.28 Billion KRW | 117.58% |
| 2015 Q1 | 116.56 Billion KRW | -3.34% |
| 2015 Q4 | 484.18 Billion KRW | 181.9% |
| 2015 Q3 | 171.75 Billion KRW | 17.01% |
| 2014 Q1 | 104.32 Billion KRW | -7.83% |
| 2014 Q4 | 120.58 Billion KRW | 25.33% |
| 2014 Q3 | 96.21 Billion KRW | -5.09% |
| 2014 FY | 422.5 Billion KRW | 1.45% |
| 2014 Q2 | 101.37 Billion KRW | -2.82% |
| 2013 Q4 | 113.18 Billion KRW | 6.83% |
| 2013 Q1 | 96.02 Billion KRW | -6.14% |
| 2013 Q3 | 105.94 Billion KRW | 4.58% |
| 2013 Q2 | 101.3 Billion KRW | 5.51% |
| 2013 FY | 416.45 Billion KRW | 5.52% |
| 2012 Q4 | 102.29 Billion KRW | -2.13% |
| 2012 FY | 394.67 Billion KRW | 18.05% |
| 2012 Q2 | 107.53 Billion KRW | 33.9% |
| 2012 Q1 | 80.31 Billion KRW | 0.0% |
| 2012 Q3 | 104.52 Billion KRW | -2.8% |
| 2011 Q3 | 63.21 Billion KRW | -0.74% |
| 2011 Q1 | 60.75 Billion KRW | 0.0% |
| 2011 FY | 334.33 Billion KRW | 71.43% |
| 2011 Q2 | 63.68 Billion KRW | 4.82% |
| 2011 Q4 | - KRW | -100.0% |
| 2010 FY | 195.03 Billion KRW | 0.0% |
| 2010 Q3 | 82.52 Billion KRW | 0.0% |
| 2010 Q4 | - KRW | -100.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 46.5 Billion KRW | -1697.344% |
| Dong-A Socio Holdings Co., Ltd. | 364.1 Billion KRW | -129.562% |
| Ildong Holdings Co., Ltd. | 198.88 Billion KRW | -320.267% |
| HANDOK Inc. | 151.36 Billion KRW | -452.207% |
| Kukje Pharma Co., Ltd. | 67.22 Billion KRW | -1143.378% |
| Yuhan Corporation | 564.5 Billion KRW | -48.068% |
| Dong-A ST Co., Ltd. | 322.21 Billion KRW | -159.412% |
| SAMSUNG PHARM. Co., LTD. | 23.74 Billion KRW | -3419.827% |
| Hanall Biopharma Co.,Ltd | 75.03 Billion KRW | -1013.887% |
| Ilyang Pharmaceutical Co.,Ltd | 198.96 Billion KRW | -320.109% |
| Dong Sung Bio Pharm.Co.,Ltd. | 40.64 Billion KRW | -1956.246% |
| MYUNGMOON Pharm co.,Ltd | 94.51 Billion KRW | -784.359% |
| Hana Pharm Co., Ltd. | 140.85 Billion KRW | -493.413% |
| Yuyu Pharma, Inc. | 46.5 Billion KRW | -1697.344% |
| Ilsung Pharmaceuticals Co., Ltd. | 34.71 Billion KRW | -2307.711% |
| REYON Pharmaceutical Co., Ltd. | 76.81 Billion KRW | -988.094% |
| Aprogen pharmaceuticals,Inc. | -12.04 Billion KRW | 7039.09% |
| JW Holdings Corporation | 446.15 Billion KRW | -87.346% |
| Ildong Pharmaceutical Co., Ltd. | 207.53 Billion KRW | -302.747% |
| Chong Kun Dang Pharmaceutical Corp. | 655.34 Billion KRW | -27.545% |
| JW Pharmaceutical Corporation | 335.67 Billion KRW | -149.01% |
| Shin Poong Pharm.Co.,Ltd. | 78.61 Billion KRW | -963.163% |
| Hyundai Pharmaceutical Co., Ltd. | 75.23 Billion KRW | -1010.948% |
| Samil Pharmaceutical Co.,Ltd | 72.21 Billion KRW | -1057.51% |
| Jeil Pharmaceutical Co.,Ltd | 183.81 Billion KRW | -354.728% |
| Yuyu Pharma, Inc. | 46.5 Billion KRW | -1697.344% |
| Kwang Dong Pharmaceutical Co., Ltd. | 295.11 Billion KRW | -183.227% |
| Daewoong pharmaceutical Co.,Ltd | 681.55 Billion KRW | -22.641% |
| JW Pharmaceutical Corporation | 335.67 Billion KRW | -149.01% |
| Yuhan Corporation | 564.5 Billion KRW | -48.068% |
| Jeil Pharma Holdings Inc | 201.82 Billion KRW | -314.155% |
| Yungjin Pharm. Co., Ltd. | 70.93 Billion KRW | -1078.273% |
| Suheung Co., Ltd. | 99.02 Billion KRW | -744.068% |
| JW Pharmaceutical Corporation | 335.67 Billion KRW | -149.01% |
| Samjin Pharmaceuticals Co., Ltd. | 145.89 Billion KRW | -472.93% |
| Korea United Pharm Inc. | 173.48 Billion KRW | -381.795% |
| CKD Bio Corp. | 5.01 Billion KRW | -16582.744% |
| Daewon Pharmaceutical Co., Ltd. | 254.23 Billion KRW | -228.777% |
| Dongwha Pharm.Co.,Ltd | 184.12 Billion KRW | -353.962% |
| Whan In Pharm Co.,Ltd. | 98.12 Billion KRW | -751.824% |
| Shin Poong Pharm.Co.,Ltd. | 78.61 Billion KRW | -963.163% |
| Chong Kun Dang Holdings Corp. | 371.49 Billion KRW | -124.996% |
| Boryung Corporation | 333.26 Billion KRW | -150.805% |
| Bukwang Pharmaceutical Co., Ltd. | 50.04 Billion KRW | -1570.191% |
| Ilyang Pharmaceutical Co.,Ltd | 198.96 Billion KRW | -320.109% |
| JW Lifescience Corporation | 51.32 Billion KRW | -1528.556% |